DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting

On June 3, 2019 DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies reported clinical updates from the Company’s ongoing first- and second-line trials in patients with MGMT-unmethylated glioblastoma multiforme (GBM) at a key opinion leader (KOL) forum focused on brain tumors and the role of VAL-083 to address the unmet medical need in GBM during the 2019 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting in Chicago, IL (Press release, DelMar Pharmaceuticals, JUN 3, 2019, View Source;and-second-line-trials-in-patients-with-mgmt-unmethylated-glioblastoma-at-a-key-opinion-leader-forum-during-the-american-society-of-clinical-oncology-asco-annual-meeting [SID1234536806]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the KOL forum, the Company provided an update on the ongoing Phase 1/2 clinical study investigating the front line treatment of VAL-083 with radiation therapy in newly diagnosed MGMT-unmethylated GBM. This trial is being conducted at the Sun Yat-sen University Cancer Center (SYSUCC) in Guangzhou, China in collaboration with Guangxi Wuzhou Pharmaceutical Company. The trial is designed to enroll up to 30 patients to determine if first-line therapy with VAL-083 treatment, in lieu of first-line temozolomide, improves progression free survival (PFS).

As of May 17, 2019, eighteen patients have been enrolled in the trial. Of these patients, fifteen have received their post-cycle 3 MRI and investigator assessment, and ten have received their post-cycle 7 MRI and investigator assessment. Two patients have not been on the study long enough to reach their first assessment, and one patient died before their first assessment. Assessments are based on the trial investigator’s clinical and radiologic assessment, according to the Response Assessment in NeuroOncology (RANO) criteria. For the fifteen patients who have received at least one assessment, eight patients were assessed with a best response of "Complete Response" (8/15, 53.3% CR) and seven patients were assessed with a best response of "Stable Disease" (7/15, 46.7% SD). Fourteen of the eighteen patients were still alive at the data cut-off date.

The Company also provided an update on the ongoing second-line Phase 2 clinical study of VAL-083 in patients with MGMT-unmethylated, Bevacizumab-naïve recurrent GBM. This study is being conducted in collaboration with The University of Texas MD Anderson Cancer Center (MDACC). This biomarker-driven trial (testing for MGMT methylation status) has been amended to enroll up to 83 patients (35 with a starting dose of 40 mg/m2; 48 with a starting dose of 30 mg/m2) to determine the potential of VAL-083 treatment to improve overall survival compared to historical reference control of 7.2 months with lomustine.

As of May 5, 2019, 51 patients have been enrolled, 35 patients at a starting dose of 40 mg/m2, and 16 patients at a starting dose of 30 mg/m2.
For the 47 patients who have been on study long enough to be assessed at the post-cycle 2 MRI:
9/35 (25.7%) patients initially receiving 40 mg/m2 exhibited "Stable Disease" per investigator assessment at the end of cycle 2
4/12 (33.3%) patients initially receiving 30 mg/m2 exhibited "Stable Disease" per investigator assessment at the end of cycle 2
Additionally, the study protocol has been amended to include enrollment of up to 24 newly-diagnosed GBM patients who have completed chemoradiation treatment with TMZ and received no subsequent TMZ maintenance therapy but will receive VAL-083 instead (Group 2). This Group has been included to explore whether earlier intervention with VAL-083 instead of TMZ maintenance therapy offers clinical benefit and extends the time to recurrence as compared to TMZ maintenance therapy.

Consistent with prior studies, myelosuppression (primarily thrombocytopenia and neutropenia) is the most common adverse event in both ongoing clinical trials.

"We are pleased with the progress to date with our two Phase 2 programs for VAL-083. In our view, these results support the preclinical and prior clinical efficacy that was observed in the MGMT-unmethylated GBM population. Additionally, we continue to view the 2017 revised NCCN guidelines for MGMT-unmethylated GBM patients quite favorably for VAL-083, which cautions against the use of temozolomide (TMZ) for this particular patient population. The MGMT-unmethylated patients represent over 60% of the GBM cases and the revised NCCN guidelines expand the therapeutic opportunity for VAL-083 to all major lines of GBM treatment from front-line and maintenance as well as second line (recurrent) GBM," commented Saiid Zarrabian, DelMar’s Chief Executive Officer.

About VAL-083

VAL-083 (dianhydrogalactitol) is a "first-in-class", bifunctional DNA-targeting agent that introduces inter-strand DNA cross-links at the N7-position of guanine leading to DNA double-strand breaks and cancer cell death. VAL-083 has demonstrated clinical activity against a range of cancers including GBM and ovarian cancer in historical clinical trials sponsored by the U.S. National Cancer Institute (NCI). DelMar has demonstrated that VAL-083’s anti-tumor activity is unaffected by common mechanisms of chemoresistance, including MGMT, in cancer cell models and animal studies. Further details regarding these studies can be found at:

View Source

VAL-083 has been granted orphan drug designations by the U.S. FDA Office of Orphan Products for the treatment of glioma, medulloblastoma and ovarian cancer, and in Europe for the treatment of malignant gliomas. VAL-083 has been granted fast-track status for the treatment of recurrent GBM by the US FDA

NantKwest to Present and Provide Update at Upcoming Jefferies 2019 Annual Healthcare Conference

On June 3, 2019 NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, reported that Dr. Patrick Soon-Shiong and Company management will be participating in the Jefferies 2019 Annual Healthcare Conference being held in New York City from June 4th-7th, 2019 (Press release, NantKwest, JUN 3, 2019, https://ir.nantkwest.com/news-releases/news-release-details/nantkwest-present-and-provide-update-upcoming-jefferies-2019?field_nir_news_date_value[min]=2019 [SID1234536825]). The presentations and one-on-one discussions will feature a science/medicine review, along with a clinical update provided by Dr. Soon-Shiong and Company management.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Details:

Event: Jefferies 2019 Annual Healthcare Conference
Date/Time: Tuesday, June 4, 2019, Presentation at 8:30am ET
Location: New York, NY

Webcast Details:

A webcast of the Dr. Soon-Shiong’s presentation will available on the NantKwest website. A link to the live webcast can be accessed by visiting the Investors page of the Company’s website. In addition, a replay of the event will be posted on the website after the event and will be available for 30 days following the event.

For more information regarding NantKwest, please visit www.nantkwest.com.

Innovent Provides Updates on Extended Follow-up on Sintilimab for Relapsed/Refractory Classical Hodgkin’s Lymphoma

On June 3, 2019 Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, reported that the results of extended follow-up on sintilimab, the anti-PD-1 antibody that co-developed with Eli Lilly and Company, for relapsed/refractory classical Hodgkin’s lymphoma (r/r cHL) (ORIENT-1) were presented by poster at the 55th annual meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) [Abstract #7533; Monday, June 3, 8:00 AM -11:00 AM CDT] (Press release, Innovent Biologics, JUN 3, 2019, View Source [SID1234536843]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As the top and most influential international oncology conference, ASCO (Free ASCO Whitepaper) Annual Meeting provides the most important platform for publishing and discussing cutting edge clinical studies. Under the theme "Caring for Every Patient, Learning from Every Patient," 2019 ASCO (Free ASCO Whitepaper) Annual Meeting has attracted numerous top oncologists, scholars, staff from regulatory and patient organizations to share the latest updates and achievements in clinical oncology, with the ultimate goal to help deliver more promising medicines and treatment options to cancer patients.

It is worth noting that more and more Chinese companies choose to participate and disclose their programs in ASCO (Free ASCO Whitepaper), showcasing the importance of emerging Chinese biotech industry. As a leading Chinese biotech company, Innovent will provide key result update of several clinical studies at the ASCO (Free ASCO Whitepaper) 2019 Annual Meeting. The results on the treatment of relapsed or refractory extranodal NK/T cell lymphoma (ORIENT-4) with sintilimab will be presented in an oral session, and key data from several other clinical studies will be presented by posters and other sessions.

ORIENT-1, led by Professor Yuan-kai Shi, Associate Dean of the Cancer Hospital of the Chinese Academy of Medical Sciences and Director of the Department of Oncology, is a multicenter, single-arm, Phase II study in China, evaluating the efficacy and safety of sintilimab for the treatment of patients with relapsed/refractory classical Hodgkin’s lymphoma. Currently, ORIENT-1 study has the largest cohort of cHL patients in China with a total of 96 patients involved.

The primary clinical endpoint is objective response rate (ORR) as assessed by an independent radiological review committee (IRRC) according to 2007 IWG criteria. Moreover, complete response rate (CRR) is a secondary endpoint.

As of the data cutoff on 16 Oct 2018, 72.9% of patients were continuing treatment with a median follow-up of 14 months. ORR was 85.4% (82/96, 95% CI: 76.7 ~ 91.8) based on IRRC review. Twenty-eight patients (29.2%) achieved complete response (CR) by PET scan. The median duration of response (DoR) and progression free survival (PFS) have not been reached. Sintilimab showed an acceptable safety profile during the study.

Based on the results of ORIENT-1 study, sintilimab was approved for treating patients with r/r cHL in China.

The extended follow-up shows that the primary endpoint, ORR, has increased to 85.4% and the secondary endpoint, CR by PET scan, has increased to 29.2 %. Innovent intends to continue updating the response and survival rate for patients who have received sintilimab in this clinical trial.

About Tyvyt (sintilimab injection)

Tyvyt (sintilimab injection) is an innovative drug jointly developed in China by Innovent and Eli Lilly and Company. Innovent is also conducting clinical studies of sintilimab injection in the United States. Tyvyt (sintilimab injection) is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1/ PD-1 Ligand-1 (PD-L1) pathway and reactivates T-cells to kill cancer cells. Tyvyt (sintilimab injection) is the only PD-1 antibody in China branded by both a local biopharmaceutical company and a global pharmaceutical company. Tyvyt (sintilimab injection) has been granted marketing approval by the National Medical Products Administration (NMPA) for relapsed or refractory classical Hodgkin’s lymphoma (r/r cHL) and has been included in the 2019 Guidelines of Chinese Society of Clinical Oncology (CSCO) for Lymphoid Malignancies. There are currently more than twenty clinical studies using sintilimab injection, including eight registration studies that evaluate the efficacy of sintilimab injection in other solid tumors.

HiFiBiO Therapeutics and Leading Academic Institutions Demonstrate Breakthrough Single-Cell Approach for Novel Biomarker Discovery to Combat Cancer

On June 3, 2019 HiFiBiO Therapeutics, a pioneer in innovative biotherapeutics with a unique single-cell analytics platform for extensive immune profiling, reported results from a breakthrough translational study in collaboration with scientists at world-leading academic institutions. A manuscript, "High-Throughput Single-Cell ChIP-seq Identifies Heterogeneity of Chromatin States in Breast Cancer," was released online ahead of publication in Nature Genetics.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In this study, scientists from HiFiBiO Therapeutics, ESPCI Paris and the Institut Curie applied HiFiBiO Therapeutics’ proprietary single-cell CelliGO platform and unique Drug Intelligent Science (DIS) capabilities to probe why certain disease cells are resistant to available therapeutics. The team demonstrated a novel high-throughput single-cell ChIP-seq (scChIP-seq) approach that overcomes the current limitations of chromatin immunoprecipitation followed by sequencing (ChIP-seq) technologies to better understand the role chromatin heterogeneity plays in cellular differentiation and development. The team used the scChIP-seq approach to discover new biomarkers for triple negative breast cancer, which led to several patent applications.

"This publication is a major milestone for HiFiBiO Therapeutics and another example of how we are applying our proprietary single-cell technology platform to develop new solutions that can address unmet medical needs and transform patient care," said Liang Schweizer, PhD, CEO and President of HiFiBiO Therapeutics. "The new HiFiBiO scChIP-seq approach enables us and our collaborators to target more precise patient subsets and generate higher and longer lasting responses to the innovative therapeutics under development."

The new scChIP-seq approach profiles chromatin landscapes of thousands of cells in tumors and other complex biological systems with high accuracy at single-cell resolution. Using patient-derived xenograft models of acquired resistance to chemotherapy and targeted therapy for triple negative breast cancer patients, the team identified a subset of cells within the untreated drug-sensitive tumors that share a common chromatin signature with resistant cells, undetectable by using bulk approaches. This signature has the potential to lead to the discovery of new drug targets and biomarkers for patient stratification.

"We are committed to partnering with leading academic institutions, as well as pharmaceutical and biotechnology companies. We strongly believe that our proprietary CelliGO platform and unique DIS capabilities can accelerate the development of high-quality antibody drugs and enable novel biomarker discovery for better patient stratification and clinical success," said Annabelle Gérard, PhD, Senior author of the publication and Head of External Innovation at HiFiBiO Therapeutics. "Together with scientists at ESPCI Paris and the Institut Curie, we have demonstrated a new approach that enables the scientific community to decipher novel biology, understand mechanisms of action, develop more effective therapeutics, and design targeted clinical trials for patients with cancer and other complex diseases."

To read the full manuscript, please visit View Source

Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax’s SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting

On June 3, 2019 Dynavax Technologies Corporation (NASDAQ: DVAX), reported increasingly favorable results from the Phase 1b/2 (SYNERGY-001), open-label, multicenter study of the combination of SD-101 and KEYTRUDA (pembrolizumab) in advanced melanoma patients who are naïve to anti-PD-1/PD-L1 treatment (Press release, Dynavax Technologies, JUN 3, 2019, View Source [SID1234536807]). The results were presented today in a poster session at the 2019 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"To consistently see an overall response rate above 70% among advanced melanoma patients, which has historically been a difficult population to treat, is very encouraging and exciting," said Robert Janssen, M.D., chief medical officer of Dynavax. "Additionally, in response to treatment, we have seen immunologically cold tumors reach similarly high levels of immune cell activation as immunologically hot tumors."

The Phase 1b/2 clinical study (NCT02521870) in patients with advanced melanoma is ongoing. In the study, SD-101 is administered intratumorally with 8 mg in 1 lesion or 2 mg in 1–4 lesions combined with intravenous administration of 200 mg of pembrolizumab.

Key highlights from the clinical data presentation include:

Efficacy:
º The overall response rate (ORR) in the SD-101 2 mg/lesion group (76%) was higher than in the SD-101 8 mg/lesion group (49%)
º The median duration of response (DOR) in both groups has not been reached, with the lower bound of the 95% confidence interval of at least 14 months
º The 18-month progression free survival (PFS) rate in the SD-101 2 mg/lesion group (72%) was higher than in the SD-101 8 mg/lesion group (36%)
º Similar rates of responses occurred in patients with PD-L1 negative tumors and PD-L1 positive tumors
º Tumor shrinkage has been observed in both injected and non-injected lesions, including visceral lesions such as the liver and lung

Immunologically cold tumors are a therapeutic challenge for anti-PD-1 therapy; the ability of SD-101 with pembrolizumab to convert cold tumors (PD-L1 negative, low IFNγ and T cell signature at baseline) into T cell rich tumors is demonstrated by biomarker data in the samples tested
º This ability to convert cold into inflamed tumors is consistent with similar effects in head and neck squamous cell carcinoma (HNSCC) (ASCO 2019, Abstract 6039)

The superior induction of infiltrating effector immune cells in lesions treated with the 2 mg/lesion dose compared with 8 mg/lesion is consistent with the increased response observed

The combination of SD-101 and pembrolizumab was well tolerated, consistent with previous report
º AEs associated with SD-101 were transient, mild to moderate injection-site reactions and flu-like symptoms that were manageable with over-the-counter medications
º No increase in immune-related AEs over pembrolizumab monotherapy were observed
A table accompanying this announcement is available at View Source

The ORR in patients with BRAF mutant tumors who received 2 mg/lesion (n=18) was 61%
The ORR in patients with PD-L1 negative tumors who received 2 mg/lesion (n=14) was 79%
In addition, the company presented data from the Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.

Key highlights from the clinical data presentation include:

Efficacy results from the combination of SD-101 and pembrolizumab in confirmed PD-1 resistant or refractory patients demonstrated an 19.4% ORR in the SD-101 2 mg/lesion group and a 13.3% ORR in the SD-101 8 mg/lesion group
Responses were observed in SD-101 injected and non-injected lesions (including liver and lung metastases)
Responses and disease control were observed in BRAF mutant or wild type tumors
Biomarker data demonstrate that SD-101 added to pembrolizumab significantly changes the tumor microenvironment of patients that previously failed PD-1 blockade including the infiltration of activated T cells, NK cells, and B cells
The combination of SD-101 and pembrolizumab was well tolerated, consistent with previous reports
º No evidence of an increased incidence or severity of AEs over pembrolizumab monotherapy
º No increase in immune-related AEs over pembrolizumab monotherapy
º AEs associated with SD-101 were mainly mild to moderate injection-site reactions and flu-like symptoms that were manageable with over-the-counter medications
In addition, a poster titled: "Overcoming genetically based resistance mechanisms to PD-1 blockade" (Abstract No: 2584) was presented. The goal of the preclinical study was to assess mechanism-based strategies to overcome resistance to anti-PD1 therapy. Results demonstrated that even in the extreme setting of genetic resistance to PD-1 blockade by JAK1/2 LoF, resistance can be overcome by SD-101, a TLR9 agonist.

About SYNERGY-001 (KEYNOTE-184)
SYNERGY-001, previously referred to as MEL-01, is a Phase 1b/2 SYNERGY-001/KEYNOTE-184 trial in combination with KEYTRUDA which includes patients with histologically or cytologically confirmed unresectable Stage IIIC/IV melanoma. The primary endpoint of the trial is objective response rate assessed by RECIST v1.1. The secondary endpoints are safety and tolerability, progression-free survival and duration of response, with an exploratory endpoint of immunophenotype of the tumor microenvironment.

About SD-101
SD-101 is a proprietary, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide. Dynavax is evaluating SD-101 in several clinical studies to assess its safety and activity, including a Phase 2 study in combination with KEYTRUDA (pembrolizumab) in advanced melanoma and metastatic or recurrent head and neck squamous cell cancer in collaboration with Merck, and in high risk breast cancer in collaboration with I-SPY 2. Dynavax maintains all commercial rights to SD-101.